Výsledky vyhledávání - "Radka Bokorova"

Akademický článek

Aberrantly elevated suprabasin in the bone marrow as a candidate biomarker of advanced disease state in myelodysplastic syndromes

Autor: Miroslav Pribyl, Sona Hubackova, Alena Moudra, Marketa Vancurova, Helena Polackova, Tomas Stopka, Anna Jonasova, Radka Bokorova, Ota Fuchs, Jan Stritesky, Barbora Salovska, Jiri Bartek, Zdenek Hodny

Publikováno v: Molecular Oncology, Vol 14, Iss 10, Pp 2403-2419 (2020)

Myelodysplastic syndromes (MDS) are preleukemic disorders characterized by clonal growth of mutant hematopoietic stem and progenitor cells. MDS are associated with proinflammatory signaling, dysregulated immune response, and cell death in the bone ma

Externí odkaz: https://doaj.org/article/fb9c612ae072482e8ba012c2ca32f842

Zobrazit plný text záznamu

Aberrantly elevated suprabasin in the bone marrow as a candidate biomarker of advanced disease state in myelodysplastic syndromes

Autor: Ota Fuchs, Anna Jonasova, Marketa Vancurova, Jiri Bartek, Radka Bokorova, Sona Hubackova, Zdenek Hodny, Alena Moudra, Tomas Stopka, Barbora Salovska, Jan Stritesky, Helena Polackova, Miroslav Pribyl

Publikováno v: Molecular Oncology, Vol 14, Iss 10, Pp 2403-2419 (2020)
Molecular Oncology

Aberrantly expressed suprabasin (SBSN) is a novel biomarker in myelodysplastic syndrome (MDS) patients. The highest levels of SBSN, secreted from myeloid subpopulations, including myeloid‐derived suppressor cells, are detectable within bone marrow

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46d65ba407dba0b3dc2101b5d9996170
https://doaj.org/article/fb9c612ae072482e8ba012c2ca32f842

Zobrazit plný text záznamu

Preclinical Studies of PROTACs in Hematological Malignancies

Autor: Ota Fuchs, Radka Bokorova

Publikováno v: Cardiovascularhematological disorders drug targets. 21(1)

Incorrectly expressed or mutated proteins associated with hematologic malignancies have been generally targeted by chemotherapy using small-molecule inhibitors or monoclonal antibodies. But the majority of these intracellular proteins are without act

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dbc97452c039db4c463d2aace3769107
https://pubmed.ncbi.nlm.nih.gov/33687890

Zobrazit plný text záznamu

High level of full-length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide

Autor: Mikulenková D, Arnost Kostecka, Magda Siskova, Dana Sponerova, Libor Červinek, Jana Brezinova, Jaroslav Polák, Radka Bokorova, Anna Jonasova, Martin Vostry, Kyra Michalova, Radana Neuwirtova, Hana Hájková, Ota Fuchs, Jaroslav Cermak

Publikováno v: European Journal of Haematology. 95:27-34

Downregulation of cereblon (CRBN) gene expression is associated with resistance to the immunomodulatory drug lenalidomide and poor survival outcomes in multiple myeloma (MM) patients. However, the importance of CRBN gene expression in patients with m

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d75896b6eedba685f481152745c1af2
https://doi.org/10.1111/ejh.12457

Zobrazit plný text záznamu

Arsenic Trioxide Upregulates Cereblon mRNA Expression and Potentiates Sensitivity of SKM-1 and MDS-L Cells to Lenalidomide

Autor: Denisa Myslivcova, Jaroslav Cermak, Ota Fuchs, Radka Bokorova

Publikováno v: Blood. 134:5397-5397

INTRODUCTION Arsenic trioxide (ATO) was approved in the United States and Europe for the treatment of acute promyelocytic leukemia (APL). ATO was also studied in multiple myeloma (MM) and myelodysplastic syndrome (MDS), where it induced growth inhibi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2cf4938bbfc54c6ab489180a10c627c5
https://doi.org/10.1182/blood-2019-126443

Zobrazit plný text záznamu

Importance of Transcription Factor Nrf2 for Cereblon Expression and Clinical Response to Combination of Lenalidomide and Erythropoietin in Lower-Risk Myelodysplastic Syndromes

Autor: Denisa Myslivcova, Jaroslav Cermak, Dana Mikulenkova, Cyril Šálek, Jana Brezinova, Marie Lauermannova, Radka Bokorova, Kyra Michalova, Ota Fuchs, Anna Jonasova, Jaroslav Polák, Zuzana Zemanova, R. Neuwirtova, Marketa Stastna

Publikováno v: Blood. 132:5507-5507

INTRODUCTION Nrf2 (nuclear factor, erythroid-derived 2-like 2 or NF-E2-related factor 2) is a transcription factor involved in antioxidant response by reducing oxidative stress. Erythropoietin (EPO) was described as an inducer of Nrf2 in the brain. N

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::13588c40446792859036a5a9392d1e2a
https://doi.org/10.1182/blood-2018-99-115803

Zobrazit plný text záznamu

High Cereblon Expression In Lower Risk Myelodysplastic Syndromes With 5q Deletion Is Associated With The Efficacy Of Lenalidomide

Autor: Ota Fuchs, R. Neuwirtova, Magda Siskova, Anna Jonasova, Arnost Kostecka, Martin Vostry, Jana Brezinova, Jaroslav Cermak, Miroslav Caniga, Kyra Michalova, Dana Mikulenkova, Jaroslav Polák, Radka Bokorova, Dana Sponerova

Publikováno v: ResearcherID

Introduction The binding of immunomodulatory drugs (IMiDs), including lenalidomide, to CRBN is associated with cytotoxicity of IMiDs used in the treatment of multiple myeloma, myelodysplastic syndromes (MDS) and lymphomas. Cereblon (CRBN) is named fo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c29b558b74e046cac9d1d204275fd41
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000331385003167&KeyUID=WOS:000331385003167

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání